| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8e8f78a48eb4cab18a363ec9dcb5d84 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-145 |
| filingDate |
2016-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e408a31186688711d6a077fa4511198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12802228671528aa5fd97d5a1398cc56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3da8f202158027b8ce950afbbfba100a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fabc5e1e829cacc28d87e81c5d8ddce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f2bd58e10032485689c2c0b20cf4237 |
| publicationDate |
2017-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2620016-C1 |
| titleOfInvention |
Method for pneumoustic pneumonia prevention in heart recipients in early postoperative period after heart transplantation |
| abstract |
FIELD: medicine. n SUBSTANCE: recipients are isolated who have been exposed to extracorporal membrane oxygenation technology for at least 24 hours and/or at least two of the following conditions have been identified: gram negative bacteremia after surgery, intraoperative blood loss of more than 500 ml, mechanical ventilation duration of more than 12 hours in the postoperative period. Such patients receive drug or drugs having a bactericidal or bacteriostatic activity against Pneumocystis jiroveci starting from 2-3 days after the operation, for 5-6 days intravenously at a therapeutic dose. n EFFECT: reduced toxic effect of multicomponent drug therapy as a result of a differentiated approach to administration of toxic and active agents against pneumocystis. n 2 cl, 4 ex |
| priorityDate |
2016-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |